Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenous expression of interleukin-21

National Medical Journal of China

Volumn 93, Issue 4, 2013, Pages 293-299

  Zhao, Nan ^a   Zhao, Ming Feng ^b   Rajbhandary, Sajin ^a   Lu, Wen Yi ^a   Zhu, Hai Bo ^b   Ma, Li ^b   You, Quan ^b   Xiao, Xia ^b   Deng, Qi ^b   Li, Yu Ming ^b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b First Municipal Central Hospital   (China)

Author keywords

Anti leukemic effects; Cytokine induced killer cells; Interleukin 21; Leukemia

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FAS LIGAND; GAMMA INTERFERON; GRANZYME A; GRANZYME B; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; LENTIVIRUS VECTOR; LYMPHOTOXIN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TUMOR NECROSIS FACTOR ALPHA;

ANALYTIC METHOD; ANTI LEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETIC TRANSFECTION; IMMUNOPHENOTYPING; MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; RESTRICTION ENZYME DIGESTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT;

CELLS, CULTURED; CYTOKINE-INDUCED KILLER CELLS; FAS LIGAND PROTEIN; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; K562 CELLS; LYMPHOTOXIN-ALPHA; PERFORIN; RECEPTORS, INTERLEUKIN-21; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874307674     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.04.013     Document Type: Article

References (13)

1. Parrish-Novak J, Dillon S R, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000, 408: 57-63.
2. Monteleone G, Pallone F, Macdonald T T. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev, 2009, 20: 185-191.
3. 2009, 17: 627-632.
4. 2008, 24: 794-799.
5. Zhao M F, Deng Q, Li Y M, et al. Interleukin 21 enhances the expansion and anti-tumor cytotoxic activity of cytokine-induced killer cells derived from both peripheral blood and cord blood in vitro [C/OL]//ASH annual meeting. Blood, 2007, 110: 4887 [2012-07-20]. http://abstracts. hematologylibrary. org/cgi/search? sortspec = relevance&fulltext = Interleukin +21 + enhances + the +expansion + and + anti-tumor + cytotoxic + activity + of + cytok&x = 4&y = 10.
6. Hashmi M H, Van Veldhuizen P J. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic: melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther, 2010, 10: 807-817.
7. 2008, 31:360-364.
8. Andorsky D J, Timmerman J M. Interleukin21: biology and application to cancer therapy. Expert Opin Biol Ther, 2008, 8: 1295-1301.
9. Davis I D, Brady B, Kefford R F, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase II a trial. Clin Cancer Res, 2009, 15: 2123-2129.
10. Meazza R, Azzarone B, Orengo A M, et al. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol, 2011, 2011:861920.
11. Coquet J M, Kyparissoudis K, Pellicci D C, et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol, 2007, 178: 2827-2834.
12. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother, 2000, 49:335-345.
13. Takaki R, Hayakawa Y, Nelson A, et al. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol, 2005, 175: 2167-2173.